Department of Pneumology and Phtiseology, University Hospital Martin and Jessenius, Comenius University, Slovakia
Research Article
Recombinant Human Monoclonal Antibodies Casirivimab/Imdevimab use in Inhibition of the Sars-Cov-2 Virus Infection
Author(s): Monika Beliančinová, Patrícia Kleinová*, Karol Graňák, Matej Vnučák, Michal Kolorz, Marián Mokáň and Ivana Dedinská
Introduction: The spread of the SARS-CoV-2 virus has caused severe problems for healthcare facilities and infrastructure worldwide. The development of rapid diagnostic tools, effective treatment protocols, and vaccines against the pathogen has accelerated. This work aims to elucidate the benefits of recombinant human monoclonal antibodies to slow the progression of SARS-CoV-2 variant B.1.617.2 infection (delta variant).
Material and methods: This is a retrospective analysis with a 6-month follow-up involving all patients who received recombinant human monoclonal antibodies (MABs) Casirivimab/Imdevimab at University Hospital Martin in November and December of 2021.
Results: A total of 180 patients were enrolled in the cohort with a mean time to administration of symptoms were 6.01 ± 0.3 days in the group of v.. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 